Back to search results
NCT07589894

Binocular and Monocular Distance-Corrected Visual Performance and Defocus Characteristics of Clareon Truplus Intraocular Lens (IOL)

Enrolling by Invitation
Not specifiedAges 50–80Observational
Colvard Kandavel Eye Center
~50 participants
Updated 2026-05-26 on ClinicalTrials.gov
What's tested:Clareon TruPlus IOL

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Binocular distance-corrected intermediate visual acuity (DCIVA) and Logarithm of the Minimum Angle of Resolution (logMAR) at 66cm at 12 weeks after second eye surgery
Measured over Baseline and 12 weeks after second eye surgery

Conditions

Cataract
Cataract Surgery
Cataract Bilateral
Cataract (Post-operative Cataract Surgery Follow-up)

Explore related trials

Cataract

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Ganesha R Kandavel, MD · PRINCIPAL_INVESTIGATOR · Coilvard-Kandavel Eye Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able and willing to understand and sign informed consent.
Able and willing to complete all required study visits.
Diagnosed with age-related cataracts in both eyes (OU)
Bilateral age-related cataract scheduled for phacoemulsification in both eyes by a single surgeon.
Surgeon predicts postoperative best corrected distance visual acuity (BCDVA) of ≥ 20/25 or better with Manifest Refractive Spherical Equivalent (MRSE) ±0.50 D of plano and in each eye post-operatively.
Clear intraocular media aside from cataract.
Will receive TruPlus bilaterally
Postoperative residual astigmatism ≤ 0.75 D in both eyes.
Refractive target: Emmetropia OU
Patient groups agreeing to either Femtosecond Laser Assisted Cataract Surgery (FLACS) or Standard phaco

Exclusion

Ocular comorbidities affecting visual outcomes, including but not limited to:
Macular disease (e.g., Age-Related Macular Degeneration \[AMD\], Diabetic Macular Edema \[DME\], Epiretinal Membrane \[ERM\]).
Active ocular inflammation.
Any investigator-determined condition likely to confound postoperative visual performance.
Strabismus with or without amblyopia in either eye.
Prior anterior or posterior segment surgery, including corneal refractive procedures.
History of retinal detachment.
Degenerative retinal or visual disorders deemed clinically significant by the investigator.
Diagnosed glaucoma (of any stage, if deemed vision-impacting by investigator).
Systemic conditions that could affect healing or study outcomes (e.g., immunocompromised, connective tissue disease, clinically significant atopy, diabetes).

What this trial measures

  • Binocular distance-corrected intermediate visual acuity (DCIVA) and Logarithm of the Minimum Angle of Resolution (logMAR) at 66cm at 12 weeks after second eye surgeryBaseline and 12 weeks after second eye surgery